Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2006

01-08-2006 | Original Paper

Predictors of Clinical Response to Systemic Steroids in Active Ulcerative Colitis

Authors: Isabel Bernal, Míriam Mañosa, Eugeni Domènech, Esther Garcia-Planella, Mercè Navarro, Vicente Lorenzo-Zúñiga, Eduard Cabré, Miquel Àngel Gassull

Published in: Digestive Diseases and Sciences | Issue 8/2006

Login to get access

Abstract

Although systemic steroids remain as the gold standard for the treatment of acute moderate to severe active ulcerative colitis (UC), 15–57% of patients do not achieve clinical remission. We sought to identify clinical, biological, or radiologic predictive factors of response to steroid treatment in acute UC attacks. The medical records of 39 consecutive patients admitted for an acute attack of UC and treated with systemic steroids, were reviewed. Epidemiologic, demographic, and clinical data at baseline and clinical data 3 days after starting steroid treatment were registered. Treatment failure was defined as the need of IV cyclosporine or colectomy before hospital discharge. Twenty-four patients (62%) responded to systemic steroids. Thirteen out of the 15 nonresponders, were treated with IV cyclosporine, avoiding colectomy in 7 cases (54%). More than six bowel movements per day at the third day of treatment, blood in stools in the third day of therapy, extensive UC, and the presence of malnutrition were associated with steroid treatment failure, but only blood in stools (P=.04), and more than six movements per day (P=.012) after 3 days of treatment, were found to be independent predictive factors of steroid refractoriness. In conclusion, clinical evaluation 3 days after starting systemic steroids seems to be the best tool to assess short-term prognosis.
Literature
1.
go back to reference Faubion WA Jr, Loftus EW Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260PubMedCrossRef Faubion WA Jr, Loftus EW Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260PubMedCrossRef
2.
go back to reference Järnerot G, Rolny P, Sandberg-Gertzen H (1985) Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89:1005–1013PubMed Järnerot G, Rolny P, Sandberg-Gertzen H (1985) Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89:1005–1013PubMed
3.
go back to reference Meyers S, Level PK, Feuer EJ, Johnson JW, Janowitz HD (1987) Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results a prospective randomized, double-blind trial. J Clin Gastroenterol 9:50–54PubMedCrossRef Meyers S, Level PK, Feuer EJ, Johnson JW, Janowitz HD (1987) Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results a prospective randomized, double-blind trial. J Clin Gastroenterol 9:50–54PubMedCrossRef
4.
go back to reference Domènech E, Garcia-Planella E, Bernal I, Rosinach M, Cabré E, Fluvià L, Boix J, Gassull MA (2002) Azathioprine without oral cyclosporine in the long-term maintenance of remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Aliment Ther Pharmacol 16:2061–2065CrossRef Domènech E, Garcia-Planella E, Bernal I, Rosinach M, Cabré E, Fluvià L, Boix J, Gassull MA (2002) Azathioprine without oral cyclosporine in the long-term maintenance of remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Aliment Ther Pharmacol 16:2061–2065CrossRef
5.
go back to reference Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grännö Ch, et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811PubMedCrossRef Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Grännö Ch, et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128:1805–1811PubMedCrossRef
6.
go back to reference Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170:2–6PubMedCrossRef Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170:2–6PubMedCrossRef
7.
go back to reference Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on the therapeutic trial. Br Med J 2:1041–1048PubMed Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on the therapeutic trial. Br Med J 2:1041–1048PubMed
8.
go back to reference Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW, Jewell DP (1996) Predicting outcome in severe ulcerative colitis. Gut 38:905–910PubMedCrossRef Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW, Jewell DP (1996) Predicting outcome in severe ulcerative colitis. Gut 38:905–910PubMedCrossRef
9.
go back to reference Benazzato L, D’Incà R, Grigoletto F, Perissinotto E, Medici V, Angriman I, Sturniolo GC (2004) Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 36:461–466PubMedCrossRef Benazzato L, D’Incà R, Grigoletto F, Perissinotto E, Medici V, Angriman I, Sturniolo GC (2004) Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 36:461–466PubMedCrossRef
10.
go back to reference Ho GT, Mowat C, Goddard CJR, Fennell JM, Shah NB, Prescott RJ, Satsangi J (2004) Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 19:1079–1087PubMedCrossRef Ho GT, Mowat C, Goddard CJR, Fennell JM, Shah NB, Prescott RJ, Satsangi J (2004) Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 19:1079–1087PubMedCrossRef
11.
go back to reference Lindgren SC, Flood ML, Kilander AF (1998) Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10:831–835PubMedCrossRef Lindgren SC, Flood ML, Kilander AF (1998) Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10:831–835PubMedCrossRef
12.
go back to reference Oshitani N, Kitano A, Fukushima R, Okabe H, Kashima K, Nakamura S, Obata A, Matsumoto T, Okawa K, Kobayashi K (1990) Predictive factors for the response of ulcerative colitis patients during the acute phase treatment. Digestion 46:107–113PubMedCrossRef Oshitani N, Kitano A, Fukushima R, Okabe H, Kashima K, Nakamura S, Obata A, Matsumoto T, Okawa K, Kobayashi K (1990) Predictive factors for the response of ulcerative colitis patients during the acute phase treatment. Digestion 46:107–113PubMedCrossRef
13.
go back to reference Chakravarty BJ (1993) Predictor and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 88:852–855PubMed Chakravarty BJ (1993) Predictor and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 88:852–855PubMed
14.
go back to reference Carbonnel F, Gargouri D, Lémman M, Beaugerie L, Cattan S, Cosnes J, Gendre JP (2000) Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 14:273–279PubMedCrossRef Carbonnel F, Gargouri D, Lémman M, Beaugerie L, Cattan S, Cosnes J, Gendre JP (2000) Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 14:273–279PubMedCrossRef
15.
go back to reference Chew CN, Nolan DJ, Jewell DP (1991) Small bowel gas in severe ulcerative colitis. Gut 32:1535–1537.PubMedCrossRef Chew CN, Nolan DJ, Jewell DP (1991) Small bowel gas in severe ulcerative colitis. Gut 32:1535–1537.PubMedCrossRef
16.
go back to reference Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR (1996) Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 71:431–436PubMedCrossRef Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR (1996) Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 71:431–436PubMedCrossRef
17.
go back to reference Vega R, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, et al (1999) Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 94:1053–1056PubMedCrossRef Vega R, Bertrán X, Menacho M, Domènech E, Moreno de Vega V, Hombrados M, et al (1999) Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 94:1053–1056PubMedCrossRef
18.
go back to reference Cottone M, Pietrosi G, Martorana G, Casà S, Pecoraro G, Oliva L, et al (2001) Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 96:773–775PubMedCrossRef Cottone M, Pietrosi G, Martorana G, Casà S, Pecoraro G, Oliva L, et al (2001) Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 96:773–775PubMedCrossRef
19.
go back to reference Vega R, Domènech E, Hernández A, Ojanguren I, Garcia-Planella E, Bernal I, et al (2004) Prospective study on the prevalence and clinical relevance of cytomegalovirus (CMV) infection in ulcerative colitis (UC). Gastroenterology 126 Suppl 2:A469 Vega R, Domènech E, Hernández A, Ojanguren I, Garcia-Planella E, Bernal I, et al (2004) Prospective study on the prevalence and clinical relevance of cytomegalovirus (CMV) infection in ulcerative colitis (UC). Gastroenterology 126 Suppl 2:A469
20.
go back to reference Forcione DG, Rosen MJ, Kisiel JB, Sands BE (2004) Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53:1117–1122PubMedCrossRef Forcione DG, Rosen MJ, Kisiel JB, Sands BE (2004) Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53:1117–1122PubMedCrossRef
Metadata
Title
Predictors of Clinical Response to Systemic Steroids in Active Ulcerative Colitis
Authors
Isabel Bernal
Míriam Mañosa
Eugeni Domènech
Esther Garcia-Planella
Mercè Navarro
Vicente Lorenzo-Zúñiga
Eduard Cabré
Miquel Àngel Gassull
Publication date
01-08-2006
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9103-7

Other articles of this Issue 8/2006

Digestive Diseases and Sciences 8/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.